Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This purpose of this study is to evaluate the safety and to find the optimal dose in
participants with human epidermal growth factor receptor 2 (HER2) positive breast cancer who
are given the combination of Interferon-gamma with paclitaxel, trastuzumab and pertuzumab.
This study will also look at other effects of Interferon-gamma with paclitaxel, trastuzumab
and pertuzumab, including its effect on this type of cancer.
Interferon-gamma is a biologically manufactured protein that is similar to a protein the body
makes naturally. In the body, interferon gamma is produced by immune cells and helps to
prevent serious infections.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute